Drugs / Epinephrine
Epinephrine
also known as
Adrenaline · Adrenalin · E004 · Adrenalin (epinephrine) · epi · DESF · Emerade · Epinephrin · +10 more
Regulatory milestones approvals, filings & regulatory actions · 12 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (2) | US (FDA) | NEFFY | — | 2025-03-05 – 2026-03-26 | fda.gov ↗ |
| Approved | EU (EMA) | Eurneffy | — | 2024-08-22 | europa.eu ↗ |
| Rejected (CRL) | US (FDA) | — | — | 2020-01-24 | ““ MINOR ” Complete Response Letter (“CRL”) for its Abbreviated New Drug Application (“ANDA”) for Epinephrine Injection, USP” amphastar.com ↗ |
| Label expansion | US (FDA) | ADRENALIN | — | 2019-01-29 | fda.gov ↗ |
| Label expansion | US (FDA) | SYMJEPI | — | 2018-09-27 | fda.gov ↗ |
| Label expansion | US (FDA) | AUVI-Q | — | 2017-11-17 | fda.gov ↗ |
| Label expansions (2) | US (FDA) | EPINEPHRINE | — | 2015-10-23 – 2016-02-11 | fda.gov ↗ |
| Label expansion | US (FDA) | SUS-PHRINE SULFITE FREE | — | 2007-12-07 | fda.gov ↗ |
| Label expansion | US (FDA) | ADRENACLICK | — | 2004-05-28 | fda.gov ↗ |
| Approved | US (FDA) | XYLOCAINE DENTAL WITH EPINEPHRINE | — | 1948-11-19 | fda.gov ↗ |
Trials 208 · started per year
today
US approved 1948
EU approved 2024
1
1
1
1
3
2
4
2
2
6
4
8
5
6
7
13
14
12
15
13
11
9
11
9
14
15
12
5
19471948194919501951195219531954195519561957195819591960196119621963196419651966196719681969197019711972197319741975197619771978197919801981198219831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 05 trials | ||||||
| Phase 0 | NCT06416969 | Jan 2024 → Jan 2028 expected | obesity disorder | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 0 | NCT04148261 | Dec 2020 → Dec 2022 | depressive disorder | Stanford University | Withdrawn | No outcome recorded |
| Phase 0 | NCT04019834 | Jul 2020 → Nov 2021 | breast cancer | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 0 | NCT05037812 | Mar 2019 → Mar 2028 expected | — | University of Utah | Active not recruiting | No outcome recorded |
| Phase 0 | NCT02692313 | Jun 2016 → Sep 2025 | — | University of Maryland, Baltimore | Completed | No outcome recorded |
| Phase 113 trials | ||||||
| Phase 1 | NCT07038746 | Aug 2025 → Jun 2026 overdue | anaphylaxis | Dr. George Luciuk | Recruiting | No outcome recorded |
| Phase 1 | NCT07703982 | Dec 2024 → Mar 2025 | hypersensitivity reaction disease | Aquestive Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT06445374 | Jul 2024 → Apr 2025 | anaphylaxis | Dr. George Luciuk | Completed | No outcome recorded |
| Phase 1 | NCT06013150 | Oct → Dec 2023 | anaphylaxis | De Motu Cordis | Completed | No outcome recorded |
| Phase 1 | NCT05986266 | Feb → Aug 2023 | uterine benign neoplasm | Egymedicalpedia | Completed | No outcome recorded |
| Phase 1 | NCT05670808 | Feb → Jun 2023 | — | Dow University of Health Sciences | Unknown | No outcome recorded |
| Phase 1 | NCT05062356 | Nov 2021 → Aug 2024 | chronic pain syndrome | St. Mary's Research Center, Canada | Completed | No outcome recorded |
| Phase 1 | NCT04696822 | Nov 2020 → Sep 2021 | anaphylaxis | Nasus Pharma | Completed | No outcome recorded |
| Phase 1 | NCT03441412 | Feb → Mar 2018 | — | Vastra Gotaland Region | Completed | No outcome recorded |
| Phase 1 | NCT03399435 | Jan → Sep 2018 | — | Grünenthal GmbH | Terminated | No outcome recorded |
| Phase 1 | NCT03282929 | Mar 2017 → Sep 2018 | anaphylaxis | Bausch & Lomb Incorporated | Completed | No outcome recorded |
| Phase 1 | NCT04551703 | Jul 2016 → Aug 2020 | chronic rhinosinusitis | Jordan University of Science and Technology | Completed | No outcome recorded |
| Phase 1 | NCT01032798 | May 2007 → May 2008 | — | University of Campinas, Brazil | Completed | No outcome recorded |
| Phase 1/29 trials | ||||||
| Phase 1/2 | NCT07228325 | Nov 2025 → Mar 2026 overdue | allergic disease, anaphylaxis | Nasus Pharma | Enrolling by invitation | No outcome recorded |
| Phase 1/2 | NCT06447194 | Oct 2025 → Jan 2027 | intervertebral disk degenerative disorder, lumbar spinal stenosis, spondylolisthesis | University of Maryland, Baltimore | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT06205134 | Aug 2023 → Feb 2024 | anaphylaxis | Nasus Pharma | Completed | No outcome recorded |
| Phase 1/2 | NCT03970655 | Sep 2019 → Jan 2026 overdue | chronic rhinosinusitis | University of Florida | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03780478 | Jun 2019 → Dec 2021 | — | University of Southern California | Unknown | No outcome recorded |
| Phase 1/2 | NCT01188577 | Aug → Sep 2010 | asthma | Amphastar Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT01143051 | Jan → Jun 2010 | asthma | Amphastar Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT01025648 | Dec 2009 | asthma | Amphastar Pharmaceuticals, Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT00977028 | Jan 2005 → Jul 2011 | — | Klein, Jeffrey A., M.D. | Unknown | No outcome recorded |
| Phase 215 trials | ||||||
| Phase 2 | NCT06270147 | Nov 2024 → Jan 2025 overdue | substance-related disorder | McMaster University | Recruiting | No outcome recorded |
| Phase 2 | NCT06478797 | Jul 2024 → Jul 2025 | infectious disease with sepsis | NATALIA LOPERA MUNERA | Unknown | No outcome recorded |
| Phase 2 | NCT06789549 | Jan → Mar 2024 | — | Padjadjaran University | Completed | No outcome recorded |
| Phase 2 | NCT05355597 | Jan 2021 → Mar 2025 | musculoskeletal system disorder, soft tissue neoplasm | Atlantic Health System | Terminated | No outcome recorded |
| Phase 2 | NCT05324995 | Jan 2021 → Feb 2022 | — | Isfahan University of Medical Sciences | Completed | No outcome recorded |
| Phase 2 | NCT03865147 | Jan → Jul 2019 | — | Medical Ethics UK Ltd | Unknown | No outcome recorded |
| Phase 2 | NCT03549221 | Jan → Oct 2018 | — | Mahidol University | Unknown | No outcome recorded |
| Phase 2 | NCT02585531 | Nov 2015 → Feb 2017 | bronchiolitis | Hospital General Naval de Alta Especialidad - Escuela Medico Naval | Unknown | No outcome recorded |
| Phase 2 | NCT02591771 | Oct 2015 → Jul 2017 | cardiogenic shock | Niguarda Hospital | Completed | No outcome recorded |
| Phase 2 | NCT01202487 | Apr 2011 → Jan 2012 | — | Children's Hospital of Eastern Ontario | Completed | No outcome recorded |
| Phase 2 | NCT01255709 | Dec 2010 → Jan 2011 | asthma | Amphastar Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00980616 | Sep 2009 → Sep 2010 | — | University Hospital, Clermont-Ferrand | Completed | No outcome recorded |
| Phase 2 | NCT00678145 | Mar 2008 → Aug 2018 | autonomic nervous system disorder, hypoglycemia, type 1 diabetes mellitus | Albert Einstein College of Medicine | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00121524 | Jan 2003 → May 2008 | cardiac arrest | Petter Andreas Steen | Completed | No outcome recorded |
| Phase 2 | NCT00134212 | Mar 2002 → Jun 2004 | infectious disease with sepsis | Rennes University Hospital | Completed | No outcome recorded |
| Phase 2/38 trials · 1 met primary · 1 missed | ||||||
| Phase 2/3 | NCT07045701 | Jun 2025 → Jun 2026 overdue | food allergy | Nasus Pharma | Enrolling by invitation | No outcome recorded |
| Phase 2/3 | NCT06456255 | Nov 2024 → May 2025 overdue | hemorrhagic disease, paranasal sinus disorder | Amin Javer | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06519955 | Oct 2024 → May 2026 | developmental dysplasia of the hip | Michael C Willey | Completed | No outcome recorded |
| Phase 2/3 | NCT05166343 | Jan 2024 → Jan 2028 expected | post-cardiac arrest syndrome | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Recruiting | No outcome recorded |
| Phase 2/3 | NCT03408483 | Apr 2018 → May 2019 | — | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 2/3 | NCT03126968 | Jul 2017 → Jul 2021 | hemorrhagic disease | University of Maryland, Baltimore | Completed | Met primary |
| Phase 2/3 | NCT02586961 | Oct 2015 → Sep 2017 | acute bronchiolitis | Assistance Publique - Hôpitaux de Paris | Terminated | No outcome recorded |
| Phase 2/3 | NCT02453516 | Oct 2014 → Sep 2019 | — | Women's College Hospital | Completed | Missed primary |
| Phase 320 trials · 3 met primary · 1 missed | ||||||
| Phase 3 | NCT07442071 | Jun 2026 → Jul 2030 expected | cardiac arrest | Central Hospital, Nancy, France | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06264596 | Aug 2024 → Aug 2025 | esophageal varices with bleeding | The Guthrie Clinic | Withdrawn | No outcome recorded |
| Phase 3 | NCT06381622 | Apr → Oct 2024 | — | Nordsjaellands Hospital | Completed | Met primary |
| Phase 3 | NCT05191745 | Jan 2022 → Apr 2023 | — | Jewish General Hospital | Completed | No outcome recorded |
| Phase 3 | NCT04750070 | Aug 2021 → Jul 2025 overdue | — | International Centre for Diarrhoeal Disease Research, Bangladesh | Recruiting | No outcome recorded |
| Phase 3 | NCT04850885 | Aug 2020 → Feb 2021 | — | Tribhuvan University, Nepal | Completed | No outcome recorded |
| Phase 3 | NCT04032119 | Jan 2020 → Dec 2022 | gastric carcinoma | Chinese University of Hong Kong | Completed | Met primary |
| Phase 3 | NCT03567473 | Dec 2018 → Jan 2025 | bronchiolitis | Children's Hospital of Eastern Ontario | Completed | No outcome recorded |
| Phase 3 | NCT03513445 | Jun 2018 → Mar 2022 | intervertebral disk degenerative disorder, lumbar disk disease, spondylolisthesis | University of Minnesota | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT02740127 | Jun 2016 → May 2020 | male reproductive organ cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 3 | NCT02540070 | Aug 2014 → Dec 2017 | osteoarthritis, knee | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Unknown | No outcome recorded |
| Phase 3 | NCT02568995 | May 2014 → Sep 2016 | — | Örebro University, Sweden | Completed | No outcome recorded |
| Phase 3 | NCT02112370 | May 2014 → May 2016 | goiter, thyroid tumor | Seoul National University Hospital | Completed | Met primary |
| Phase 3 | NCT01861015 | May 2013 → Mar 2014 | leiomyoma | CHA University | Completed | No outcome recorded |
| Phase 3 | NCT01708642 | Nov 2012 → Sep 2013 | — | Rigshospitalet, Denmark | Completed | Missed primary |
| Phase 3 | NCT01737905 | Oct 2012 → Mar 2013 | asthma | Amphastar Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01476904 | Nov 2011 → Apr 2012 | asthma | Amphastar Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01357642 | Jul → Nov 2011 | asthma | Amphastar Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00446017 | Jun 2003 → Aug 2004 | heart failure | University of Luebeck | Completed | No outcome recorded |
| Phase 3 | NCT00002659 | May 1995 → ? | head and neck cancer | Matrix Pharmaceutical | Unknown | No outcome recorded |
| Phase 469 trials · 5 met primary · 6 missed | ||||||
| Phase 4 | NCT07468604 | May 2026 → May 2027 expected | dysautonomia | University Health Network, Toronto | Recruiting | No outcome recorded |
| Phase 4 | NCT07089251 | Jul 2025 → Jun 2027 expected | osteoarthritis, knee | King Abdullah International Medical Research Center | Recruiting | No outcome recorded |
| Phase 4 | NCT05972681 | Apr → Oct 2025 | — | Montefiore Medical Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT07425678 | Jan → Jul 2025 | supratentorial cancer | Aga Khan University | Completed | No outcome recorded |
| Phase 4 | NCT07006168 | Nov 2024 → Dec 2026 expected | — | The University of Hong Kong | Recruiting | No outcome recorded |
| Phase 4 | NCT05996133 | Dec 2023 → Dec 2026 expected | — | Hartford Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT06189781 | Dec 2023 → Dec 2026 expected | cerebral palsy, developmental dysplasia of the hip | University of California, Los Angeles | Recruiting | No outcome recorded |
| Phase 4 | NCT06113497 | Nov 2023 → Oct 2024 | — | Kyunghee University Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT05667727 | Oct 2023 → Jun 2025 | childhood onset asthma | Oman Medical Speciality Board | Completed | No outcome recorded |
| Phase 4 | NCT05658692 | Oct 2022 → Oct 2023 | acute respiratory distress syndrome | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Phase 4 | NCT05492968 | Sep 2022 → Aug 2024 | high output heart failure | Medical University of Vienna | Unknown | No outcome recorded |
| Phase 4 | NCT05244525 | Mar → Aug 2022 | — | The University of Texas Health Science Center, Houston | Completed | Missed primary |
| Phase 4 | NCT05029726 | Feb 2022 → Feb 2027 expected | ganglion or cyst of synovium/tendon/bursa, intervertebral disk degenerative disorder, lumbar disk disease, lumbar spinal stenosis +3 | John O'Toole | Recruiting | No outcome recorded |
| Phase 4 | NCT05292677 | Jul 2021 → Jun 2023 | laryngeal disorder | Eastern Virginia Medical School | Unknown | No outcome recorded |
| Phase 4 | NCT05413902 | Apr 2021 → Jan 2022 | — | University of Puerto Rico | Completed | No outcome recorded |
| Phase 4 | NCT07480135 | Apr → May 2021 | — | Vrije Universiteit Brussel | Completed | No outcome recorded |
| Phase 4 | NCT04699110 | Jan → Apr 2021 | acute coronary syndrome | National Institute of Cardiovascular Diseases, Pakistan | Completed | Mixed |
| Phase 4 | NCT03696199 | Sep 2020 → Sep 2027 expected | — | Lahey Clinic | Recruiting | No outcome recorded |
| Phase 4 | NCT04065451 | Jan 2020 → Aug 2021 | polyp of colon | Indiana University | Completed | Met primary |
| Phase 4 | NCT04207840 | Dec 2019 | anaphylaxis, asthma | Amphastar Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 4 | NCT03335293 | Oct → Dec 2019 | pregnancy disorder | University of Florida | Withdrawn | No outcome recorded |
| Phase 4 | NCT03794882 | May 2019 → Mar 2020 | neuropathy, painful, substance-related disorder | University of Wisconsin, Madison | Terminated | No outcome recorded |
| Phase 4 | NCT03906617 | Apr 2019 → Apr 2022 overdue | — | The Cooper Health System | Recruiting | No outcome recorded |
| Phase 4 | NCT04799184 | Apr 2019 → Aug 2021 | local anesthetic poisoning | Pontificia Universidad Catolica de Chile | Completed | No outcome recorded |
| Phase 4 | NCT03638726 | Sep 2018 → Mar 2019 | cataract | Dar El Oyoun Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03368391 | Jan → Jun 2018 | dental pulp disorder, local anesthetic poisoning | Louisiana State University Health Sciences Center in New Orleans | Unknown | No outcome recorded |
| Phase 4 | NCT03071601 | Dec 2017 → Dec 2021 | — | Centre Hospitalier le Mans | Completed | No outcome recorded |
| Phase 4 | NCT03366298 | Nov 2017 → Oct 2018 | anaphylaxis | Imperial College London | Completed | No outcome recorded |
| Phase 4 | NCT03198403 | Aug → Sep 2017 | — | Regionshospitalet Silkeborg | Completed | No outcome recorded |
| Phase 4 | NCT03862404 | Jul 2017 → Feb 2019 | — | McGill University Health Centre/Research Institute of the McGill University Health Centre | Completed | No outcome recorded |
| Phase 4 | NCT04203225 | May 2017 → Nov 2019 | — | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | Completed | Missed primary |
| Phase 4 | NCT03105674 | May → Nov 2017 | anal fistula, hemorrhoid, ulcer of anus and rectum | Columbia University | Withdrawn | No outcome recorded |
| Phase 4 | NCT03279757 | Oct → Dec 2016 | — | Netherlands Institute for Pigment Disorders | Completed | No outcome recorded |
| Phase 4 | NCT02967172 | Oct 2016 → Sep 2018 | ankle defects short stature, neuropathy, painful | University of Iowa | Completed | No outcome recorded |
| Phase 4 | NCT02980835 | Sep 2016 → Mar 2022 | — | University at Buffalo | Completed | No outcome recorded |
| Phase 4 | NCT02839356 | Jul 2016 → Dec 2017 | acute pancreatitis | Anhui Provincial Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02697955 | Jun 2016 → Feb 2017 | osteoarthritis | University of Aarhus | Completed | Met primary |
| Phase 4 | NCT02938286 | Mar → Aug 2016 | — | Netherlands Institute for Pigment Disorders | Completed | No outcome recorded |
| Phase 4 | NCT03513276 | Feb 2016 → Feb 2018 | osteoarthritis, hip | Hospital Mutua de Terrassa | Completed | Missed primary |
| Phase 4 | NCT02570503 | Oct 2015 → Feb 2021 | osteoarthritis, knee | Virginia Commonwealth University | Terminated | No outcome recorded |
| Phase 4 | NCT02571283 | Oct 2015 → May 2016 | — | University of Louisville | Withdrawn | No outcome recorded |
| Phase 4 | NCT02474654 | Jul 2015 → Jan 2019 | — | Health Sciences North Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT02548533 | Jun 2015 → Jan 2016 | — | Netherlands Institute for Pigment Disorders | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT02793947 | May 2015 → Aug 2016 | neuropathy, painful | University of Iowa | Completed | No outcome recorded |
| Phase 4 | NCT02365727 | Apr → Aug 2015 | osteoarthritis, knee | The Hawkins Foundation | Withdrawn | No outcome recorded |
| Phase 4 | NCT02369510 | Feb 2015 → May 2016 | — | Icahn School of Medicine at Mount Sinai | Completed | Met primary |
| Phase 4 | NCT02735018 | Dec 2014 → Mar 2015 | — | Rio de Janeiro State University | Completed | No outcome recorded |
| Phase 4 | NCT02696369 | Dec 2014 → Aug 2015 | impacted teeth, multiple | Huons Co., Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT02246179 | Sep → Oct 2014 | — | Netherlands Institute for Pigment Disorders | Completed | No outcome recorded |
| Phase 4 | NCT02274974 | Aug 2014 → Mar 2015 | — | Ain Shams Maternity Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02270437 | Jun 2014 → Aug 2015 | — | Peking Union Medical College Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01964781 | Aug 2013 → Dec 2014 | neuropathy, painful | St. Olavs Hospital | Completed | Met primary |
| Phase 4 | NCT01705964 | Jun 2013 → Apr 2018 | asthma | University of Louisville | Completed | No outcome recorded |
| Phase 4 | NCT01834820 | Jan 2013 → Jun 2015 | bronchiolitis | Hospital General Naval de Alta Especialidad - Escuela Medico Naval | Completed | No outcome recorded |
| Phase 4 | NCT01706952 | Dec 2012 → Dec 2013 | chronic rhinosinusitis | Marc Tewfik | Completed | Missed primary |
| Phase 4 | NCT05439460 | Jan 2012 → Jun 2014 | pulmonary arterial hypertension | Stanford University | Completed | No outcome recorded |
| Phase 4 | NCT01596998 | Dec 2011 → Apr 2012 | — | Pontificia Universidad Catolica de Chile | Completed | No outcome recorded |
| Phase 4 | NCT01756443 | Aug 2011 → Dec 2012 | — | Cork University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01243112 | May → Sep 2010 | — | Scott and White Hospital & Clinic | Completed | Missed primary |
| Phase 4 | NCT01281891 | Sep 2009 → Sep 2012 | osteoarthritis, hip | Region Örebro County | Unknown | No outcome recorded |
| Phase 4 | NCT01418118 | Oct 2008 → Feb 2010 | head and neck cancer, hypotensive disorder, oral cavity cancer | Oxford University Hospitals NHS Trust | Completed | No outcome recorded |
| Phase 4 | NCT00685672 | Aug 2008 → Jan 2016 | pain agnosia, pregnancy disorder | Oslo University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00901628 | Apr 2008 → Mar 2009 | osteoarthritis, knee | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00421967 | Jan 2007 → Mar 2008 | osteoarthritis, knee | University of Aarhus | Terminated | No outcome recorded |
| Phase 4 | NCT00318292 | Apr 2006 → Mar 2008 | neuropathy, painful | Mayo Clinic | Completed | Met primary |
| Phase 4 | NCT00270777 | Mar 2005 → Apr 2008 | snakebite envenomation | University of Kelaniya | Completed | Mixed |
| Phase 4 | NCT00289419 | Feb 2005 → Feb 2006 | osteoarthritis, hip | University of Aarhus | Completed | No outcome recorded |
| Phase 4 | NCT00127907 | May 2004 → Oct 2007 | cardiac arrest | Hospices Civils de Lyon | Completed | Missed primary |
| Phase 4 | NCT00361452 | Dec 2000 → May 2001 | respiratory syncytial virus bronchiolitis | Rambam Health Care Campus | Terminated | No outcome recorded |
| Phase not applicable69 trials · 3 met primary · 5 missed | ||||||
| — | NCT07604337 | Jun → Dec 2026 expected | delirium | seher orbay yasli | Not yet recruiting | No outcome recorded |
| — | NCT07667829 | Jun 2026 → Dec 2028 expected | chronic thromboembolic pulmonary hypertension, pulmonary arterial hypertension | China National Center for Cardiovascular Diseases | Not yet recruiting | No outcome recorded |
| — | NCT07633106 | Feb → Jul 2026 overdue | glucose metabolism disease | Dow University of Health Sciences | Active not recruiting | No outcome recorded |
| — | NCT07349407 | Dec 2025 → Nov 2026 expected | — | Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting | No outcome recorded |
| — | NCT07084753 | Jul → Sep 2025 overdue | obesity disorder | IVO JURISIC | Not yet recruiting | No outcome recorded |
| — | NCT07273526 | Jun → Dec 2025 overdue | infectious disease with sepsis | Laiba Qamar | Recruiting | No outcome recorded |
| — | NCT07436546 | Mar → Dec 2025 | impacted teeth, multiple | Postgraduate Institute of Dental Sciences Rohtak | Completed | No outcome recorded |
| — | NCT07828574 | Jan 2025 → Jun 2026 overdue | pudendal neuralgia | Irkutsk State Medical University | Active not recruiting | No outcome recorded |
| — | NCT06566352 | May 2024 → May 2025 overdue | — | Zagazig University | Recruiting | No outcome recorded |
| — | NCT06112548 | Mar 2024 → Nov 2025 | osteoarthritis, knee | Damascus University | Completed | No outcome recorded |
| — | NCT06172400 | Jan → Dec 2024 | carpal tunnel syndrome | Region Skane | Unknown | No outcome recorded |
| — | NCT06145191 | Dec 2023 → Mar 2025 | hemorrhagic disease | Clinical Hospital Centre Zagreb | Completed | No outcome recorded |
| — | NCT05990933 | Dec 2023 → Sep 2024 | hypoglycemia, inflammatory disease, type 1 diabetes mellitus | Cees Tack | Completed | No outcome recorded |
| — | NCT05908851 | Nov 2023 → Nov 2024 | — | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Unknown | No outcome recorded |
| — | NCT06896409 | Oct 2023 → Oct 2025 overdue | — | Tallaght University Hospital | Recruiting | No outcome recorded |
| — | NCT05943080 | Jun → Aug 2023 | osteoarthritis, knee | Kirsehir Ahi Evran Universitesi | Completed | No outcome recorded |
| — | NCT06030479 | Feb → Oct 2023 | placenta accreta, placenta praevia | Cairo University | Unknown | No outcome recorded |
| — | NCT05534945 | Dec 2022 → Jul 2026 overdue | — | Ciusss de L'Est de l'Île de Montréal | Recruiting | No outcome recorded |
| — | NCT05439213 | Jun 2022 → Jun 2023 | rotator cuff syndrome | Ramsay Santé | Completed | No outcome recorded |
| — | NCT05406895 | May 2022 → Mar 2024 | — | Louisiana State University Health Sciences Center in New Orleans | Completed | No outcome recorded |
| — | NCT05728151 | Feb 2022 → Apr 2024 | strabismus | Research Institute of Ophthalmology, Egypt | Completed | No outcome recorded |
| — | NCT04773405 | Mar → Nov 2021 | musculoskeletal system disorder | Chinese University of Hong Kong | Completed | No outcome recorded |
| — | NCT04282239 | Mar → Dec 2021 | — | NYU Langone Health | Withdrawn | No outcome recorded |
| — | NCT04771923 | Feb 2021 → Feb 2022 | hemorrhagic disease | Clinical Hospital Centre Zagreb | Completed | Missed primary |
| — | NCT04494100 | Sep 2020 → Jun 2021 | carpal tunnel syndrome | CMC Ambroise Paré | Completed | Met primary |
| — | NCT04562103 | Jul → Aug 2020 | local anesthetic poisoning | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Completed | No outcome recorded |
| — | NCT04131283 | May → Dec 2019 | gingival disorder | Semmelweis University | Completed | No outcome recorded |
| — | NCT03814954 | Jan 2019 → Aug 2021 | — | Makassed General Hospital | Completed | No outcome recorded |
| — | NCT03693820 | Sep 2018 → Jun 2019 | — | Alaa Mazy Mazy | Completed | No outcome recorded |
| — | NCT04029610 | Aug 2018 → Dec 2019 | — | Uri farkash | Completed | No outcome recorded |
| — | NCT03914235 | Aug 2018 → Mar 2019 | tenosynovitis | Mexican Social Security Institute | Completed | No outcome recorded |
| — | NCT03427502 | Jun 2018 → Dec 2019 | anterior deviation infundibular septum, chronic rhinosinusitis, nasal cavity polyp | Lumbini Medical College | Completed | No outcome recorded |
| — | NCT03395912 | Jan 2018 → May 2020 | — | HaEmek Medical Center, Israel | Completed | Met primary |
| — | NCT05248724 | Aug 2017 → Sep 2020 | — | Castilla-La Mancha Health Service | Completed | No outcome recorded |
| — | NCT03135340 | Aug 2017 → Nov 2018 overdue | — | University of Western Ontario, Canada | Not yet recruiting | No outcome recorded |
| — | NCT03518463 | Jun → Jul 2017 | pregnancy disorder | Mbarara University of Science and Technology | Completed | No outcome recorded |
| — | NCT03319563 | Apr → Oct 2017 | — | Mansoura University | Completed | No outcome recorded |
| — | NCT03057769 | Feb → Oct 2017 | pancreatitis | Air Force Military Medical University, China | Terminated | Missed primary |
| — | NCT04628676 | Feb 2017 → Dec 2019 | rotator cuff syndrome | Haseki Training and Research Hospital | Completed | No outcome recorded |
| — | NCT01911949 | Jan → Aug 2017 | — | McMaster University | Completed | No outcome recorded |
| — | NCT02909140 | Sep 2016 → Aug 2018 | cataract | Johns Hopkins University | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT04378283 | May 2016 → Feb 2020 | — | University Medical Center Hamburg-Eppendorf | Completed | No outcome recorded |
| — | NCT02505633 | Jul → Sep 2015 | — | Gachon University Gil Medical Center | Completed | No outcome recorded |
| — | NCT02860221 | May 2015 → Jul 2017 | — | Southwest Hospital, China | Unknown | No outcome recorded |
| — | NCT02864095 | May 2015 → Oct 2017 | — | Southwest Hospital, China | Unknown | No outcome recorded |
| — | NCT02422823 | Apr 2015 → Jun 2016 | pulpitis | Isabel Peixoto Tortamano | Completed | Missed primary |
| — | NCT02285634 | Nov 2014 → Dec 2016 | hypertensive disorder | Mayo Clinic | Completed | Missed primary |
| — | NCT02379221 | Sep 2014 → Mar 2016 | — | David Grant U.S. Air Force Medical Center | Completed | No outcome recorded |
| — | NCT02228083 | Sep 2014 → Sep 2016 | heart failure | University of Sao Paulo General Hospital | Unknown | No outcome recorded |
| — | NCT02104778 | Apr 2014 → Jun 2016 | — | Yeungnam University College of Medicine | Unknown | No outcome recorded |
| — | NCT04153123 | Dec 2013 → May 2014 | — | Federal University of Minas Gerais | Completed | No outcome recorded |
| — | NCT01800877 | Apr 2013 → Dec 2014 | hypotensive disorder | Francois Lamontagne | Completed | No outcome recorded |
| — | NCT02268019 | Jan 2013 → Jan 2015 | hypospadias | Isfahan University of Medical Sciences | Unknown | No outcome recorded |
| — | NCT01497509 | May → Nov 2012 | — | University Hospitals Cleveland Medical Center | Withdrawn | No outcome recorded |
| — | NCT01560702 | Mar 2012 → Sep 2013 | peptic ulcer disease | Zagazig University | Completed | No outcome recorded |
| — | NCT01264653 | Dec 2010 → Dec 2011 | cataract | Wenzhou Medical University | Completed | No outcome recorded |
| — | NCT01432522 | Jul 2010 → Aug 2011 | anaphylaxis | Siriraj Hospital | Completed | No outcome recorded |
| — | NCT01131741 | May → Jul 2010 | — | Seoul National University Hospital | Unknown | No outcome recorded |
| — | NCT01080625 | Apr 2010 → Sep 2011 | — | Seoul National University Hospital | Completed | No outcome recorded |
| — | NCT01264575 | Dec 2009 → Jan 2011 | — | Seoul Medical Center | Completed | No outcome recorded |
| — | NCT00523055 | May 2008 → Apr 2012 | — | University of Manitoba | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT00548886 | Feb 2008 → Jan 2012 | — | Emory University | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT00322660 | Jun 2006 → Jun 2007 | hypoglycemia, respiratory failure | Hvidovre University Hospital | Completed | Missed primary |
| — | NCT00225043 | Jun 2005 → Aug 2007 | — | New York Presbyterian Brooklyn Methodist Hospital | Completed | No outcome recorded |
| — | NCT01116609 | Oct 2004 → Nov 2009 | — | University of Aarhus | Completed | No outcome recorded |
| — | NCT00114478 | Nov 2003 → May 2006 | bronchiolitis | Kern Medical Center | Unknown | Met primary |
| — | NCT01513564 | Jan 2001 → Dec 2003 | spondylolisthesis | Northern Orthopaedic Division, Denmark | Completed | No outcome recorded |
| — | NCT00608816 | — | type 1 diabetes mellitus | Vanderbilt University | Withdrawn | No outcome recorded |
| — | NCT00605774 | — | type 1 diabetes mellitus | Vanderbilt University | Withdrawn | No outcome recorded |
| Comparator or background therapy401 trials | ||||||
| Phase 0 | NCT06345833 Background | Jul 2024 → Jul 2026 overdue | hemophilia, hemorrhagic disease | University of Minnesota | Recruiting | No outcome recorded |
| Phase 0 | NCT06149091 Comparator | Dec 2023 → Dec 2024 | bronchial disorder | China-Japan Friendship Hospital | Unknown | No outcome recorded |
| Phase 0 | NCT04630886 Background | Jun 2021 → Jan 2024 | skin neoplasm | Riley McLean | Terminated | No outcome recorded |
| Phase 0 | NCT05019638 Comparator | Mar 2021 → May 2028 expected | — | University of Utah | Active not recruiting | No outcome recorded |
| Phase 0 | NCT04263064 Comparator | Mar 2020 → Aug 2022 | — | Medical University of South Carolina | Completed | No outcome recorded |
| Show all 401 trials opens the full record — a long page | ||||||
News releases announcing trial results or a regulatory action · 30
| Date | Issuer | Release |
|---|---|---|
| 2026-09-14 | Nasus Pharma | Regulatory Nasus Pharma Announces FDA Clearance to Initiate Clinical Study of NS002 in the Treatment of Anaphylaxis nasuspharma.com ↗
Nasus Pharma Ltd. (NYSE American: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that the U.S. Food and Drug Administration (“FDA”) has cleared the Company’s Investigational New Drug (“IND”) application for NS002, its investigational intranasal epinephrine powder for the treatment of anaphylaxis. |
| 2026-06-15 | ALK-Abelló A/S | Regulatory EURneffy 1 mg approved in the UK as the first and only needle-free adrenaline treatment for young children (aged 4 and older, 15–30 kg) at risk of anaphylaxis alk.net ↗ |
| 2026-06-11 | ALK-Abelló A/S | Results Anaphylaxis management is falling short in 2026 – EAACI data suggest EURneffy, the only needle-free nasal adrenaline spray, could help close the gap alk.net ↗ |
| 2026-04-15 | ALK-Abelló A/S | Regulatory neffy® approved as the first needle-free anaphylaxis treatment of adults and children in Canada alk.net ↗
neffy ® constitutes the first approved nasal adrenaline spray for timely emergency treatment. |
| 2026-03-31 | ALK-Abelló A/S | Regulatory EURneffy 1 mg approved across the EU as the first and only needle-free adrenaline treatment for young children (≥15 kg) at risk of anaphylaxis alk.net ↗
This approval means more people with severe allergies including children aged 4 years and older (≥15 kg) will be eligible for treatment with EUR neffy ® , the only needle-free adrenaline-based product currently approved across the EU. |
| 2026-03-16 | Nasus Pharma | Results Nasus Pharma Announces Positive Top Line Data from Phase 2 Clinical Study of NS002: Achieves Significantly Superior and Faster Epinephrine Delivery Compared to EpiPen® with Accelerated Speed to Therapeutic Threshold nasuspharma.com ↗ |
| 2026-03-04 | ALK-Abelló A/S | Results New data reveals 9 in 10 people prefer EURneffy, a needle-free nasal adrenaline spray, over auto-injectors alk.net ↗
In this randomised crossover study of 90 participants, 88% significantly preferred EUR neffy ® over auto-injectors. |
| 2026-02-17 | Nasus Pharma | Results Nasus Pharma to Present Data Highlighting Superior Nasal Deposition and Stability of Intranasal Epinephrine Powder at AAAAI 2026 nasuspharma.com ↗
Nasal powder has significantly higher deposition in the nasal cavity in comparison to liquid nasal spray which could lead to enhanced blood absorption |
| 2026-02-15 | CSL Behring | Regulatory neffy, adrenaline nasal spray, now approved to treat anaphylaxis in Australia csl.com ↗
The approval of neffy is very welcome as it gives patients and their doctors a nasal administration option and choice in managing their condition. |
| 2026-01-29 | ALK-Abelló A/S | Regulatory ALK receives positive recommendation for EURneffy® 1 mg: A needle-free anaphylaxis treatment for children alk.net ↗ |
| 2026-01-20 | Nasus Pharma | Results Nasus Pharma Announces Positive Interim Results from Phase 2 Clinical Study of NS002 Intranasal Epinephrine Powder nasuspharma.com ↗
The data demonstrated that NS002 achieved faster absorption, higher peak concentrations, and greater early epinephrine exposure compared to intramuscular EpiPen ® autoinjector. |
| 2025-11-06 | Nasus Pharma | Regulatory Nasus Pharma Announces Approval from Health Canada to Initiate Planned Phase 2 Clinical Study of NS002 Intranasal Epinephrine Powder nasuspharma.com ↗
The Health Canada authorization marks an important regulatory milestone in the NS002 development program. |
| 2025-09-08 | ALK-Abelló A/S | Results Real-world evidence supports clinical effectiveness of the neffy® nasal adrenaline spray alk.net ↗
ALK (ALKB:DC / OMX: ALK B) today announced that real-world evidence evaluating the clinical performance of the nasal adrenaline spray neffy ® in US patients experiencing anaphylaxis symptoms during oral food challenge and allergen immunotherapy has been accepted for scientific publication. |
| 2025-07-18 | ALK-Abelló A/S | Regulatory EURneffy® approved as the first needle-free anaphylaxis treatment of adults and children in the UK alk.net ↗
Inside Information ALK ( ALKB:DC / OMX: ALK B ) today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has approved EUR neffy ® 2 mg in the United Kingdom (UK) for anaphylaxis treatment of adults and children (≥30 kg). |
| 2025-06-16 | ALK-Abelló A/S | Results ALK presented comprehensive data on two new paediatric AIT tablets and a nasal adrenaline spray at EAACI 2025 alk.net ↗
ALK also presented data demonstrating that the EURneffy ® adrenaline nasal spray produces a pharmacological response comparable to intramuscular adrenaline injection in patients with allergic rhinitis. |
| 2025-06-13 | ALK-Abelló A/S | Results EURneffy® adrenaline nasal spray data demonstrating a pharmacological response comparable to intramuscular adrenaline injection in patients with allergic rhinitis presented at EAACI 2025 alk.net ↗
Nasal spray delivery has been proven to provide a comparable pharmacological response to injected adrenaline across many dosing considerations, including in this study regardless of nasal congestion associated with allergic rhinitis. |
| 2024-10-24 | XenoPort, Inc. | Results Aquestive Therapeutics Announces Positive Topline Results from Oral Allergy Syndrome (OAS) Challenge Study for Anaphylm™ (epinephrine) Sublingual Film aquestive.com ↗ |
| 2024-08-07 | Nasus Pharma | Results Nasus Pharma Announces Ground-Breaking Five Years Stability of its FMXIN002 Nasal Epinephrine Powder for Severe Allergy and Anaphylaxis nasuspharma.com ↗
Epinephrine base was 97.5% at 5 years well within the defined limits (95-105% ICHQ1 ). |
| 2024-07-25 | XenoPort, Inc. | Results Aquestive Therapeutics Reports Positive Topline Data for Anaphylm™ (epinephrine) Sublingual Film from Self-Administration Study aquestive.com ↗
today released positive topline PK data from the self-administration study of Anaphylm™ (epinephrine) Sublingual Film. |
| 2024-03-14 | XenoPort, Inc. | Results Aquestive Therapeutics Announces Pivotal Study for Anaphylm™ (epinephrine) Sublingual Film Successfully Meets Primary and Secondary Endpoints and Provides Clinical Development Update Following FDA Meeting aquestive.com ↗
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today released positive topline clinical data from its Phase 3 pivotal pharmacokinetic (PK) clinical study of Anaphylm™ (epinephrine) Sublingual Film and findings from the FDA Type C meeting. |
| 2023-12-05 | Nasus Pharma | Results Nasus Pharma Announces Positive Clinical Results of Recent Phase 2 Study With FMXIN002 Intranasal Epinephrine nasuspharma.com ↗
FMXIN002 demonstrated clear and meaningful advantage both in the pharmacokinetic profile of the first 20 minutes and in the number of patients reaching drug plasma clinical threshold of Epinephrine. |
| 2023-06-19 | Orexo AB | Results OX640: Shaping the future of nasal powder epinephrine using the innovative amorphOX platform orexo.com ↗
Overall, OX640 provided a higher total epinephrine (adrenaline) exposure than the EpiPen. |
| 2022-10-11 | Orexo AB | Results Orexo announces positive data from phase 1 clinical study for OX640 - a nasal epinephrine rescue medication for allergic reactions orexo.com ↗
All four investigational formulations were extensively absorbed and rapidly achieved clinically relevant plasma levels of epinephrine comparable to the reference product. |
| 2022-08-16 | Amphastar Pharmaceuticals, Inc. | Regulatory Amphastar Pharmaceuticals Receives FDA Approval for Epinephrine Pre-Filled Syringes amphastar.com ↗
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's New Drug Application ("NDA") for Epinephrine injection USP, 1 mg/10mL (0.1 mg/mL) Single Dose Pre-Filled Syringe. |
| 2021-06-23 | Nasus Pharma | Results Nasus Pharma Announces Positive Results from a Pilot Clinical Study of FMXIN002 Intranasal Powder Epinephrine Spray in nasuspharma.com ↗
The results of the study with FMXIN002 powder intranasal Epinephrine show that it can provide a safer and more effective rescue for the emergency treatment of life- threatening allergic reactions by providing an easy-to-use device and quicker absorption of Epinephrine |
| 2020-04-27 | Amphastar Pharmaceuticals, Inc. | Regulatory Amphastar Pharmaceuticals, Inc. Receives FDA Approval for Epinephrine Injection, USP 30mg/30mL (1mg/mL) Multiple Dose Vial amphastar.com ↗
Amphastar Pharmaceuticals, Inc. , (NASDAQ: AMPH) (“Amphastar”), today announces that the U.S. Food and Drug Administration (“FDA”) has granted approval of its Abbreviated New Drug Application (“ANDA”) for Epinephrine Injection, USP 30mg/30mL (1mg/mL) Multiple Dose Vial. |
| 2020-01-28 | Amphastar Pharmaceuticals, Inc. | Regulatory Amphastar Announces the Receipt of a MINOR CRL for Epinephrine Injection, USP 30mg/30mL (1mg/mL) Multiple Dose Vial amphastar.com ↗ |
| 2018-11-08 | Amphastar Pharmaceuticals, Inc. | Regulatory Amphastar Pharmaceuticals, Inc. Announces Reintroduction of Primatene® MIST amphastar.com ↗ |
| 2016-12-27 | Amphastar Pharmaceuticals, Inc. | Regulatory Amphastar Pharmaceuticals Receives Complete Response Letter for Primatene® Mist amphastar.com ↗
Amphastar Pharmaceuticals, Inc. , (NASDAQ:AMPH) announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) to its wholly-owned subsidiary, Armstrong Pharmaceuticals, Inc. , for its New Drug Application for Primatene ® Mist (epinephrine inhalation aerosol). |
| 2010-10-13 | ALK-Abelló A/S | Regulatory ALK's new and improved adrenaline pen, JEXT®, approved in Europe alk.net ↗
The competent authorities for medicinal products in 17 European countries have just approved JEXT® for the emergency treatment of severe acute allergic reactions (anaphylaxis) caused by, for example, foods or bee stings. |
All press releases naming this drug 43 releases
Evidence & citations 22 cited values
Every value below carries the sentence it was read from. 611 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | epinephrine | “The purpose of this study was to investigate and compare pulpal anesthesia and cardiovascular parameters obtained with 0.6 ml of 4% articaine with epinephrine (1:100.000) for...” NCT03225326 ↗500“Perineural injection of articaine hydrochloride with epinephrine (20 mg/mL + 0.005 mg/mL, 5 mL) combined with triamcinolone acetonide (40 mg in 1 mL), diluted with 0.9% saline...” NCT07828574 ↗ “To investigate the role of adrenaline (epinephrine) in this response, we measured the inflammatory effects of adrenaline in a concentration and timeframe comparable to that...” PMID 41611977 ↗ Jan 2026 “Under steady state 0.2 ml kg(-1) and after 10 min 0.4 ml kg(-1) of one of the following three test solutions was administered i.v.: bupivacaine 0.125% (Group 1), bupivacaine...” PMID 19915187 ↗ Jan 2010 “The pain cocktail includes three medications: ropivacaine (a local anesthetic), ketorolac (an anti-inflammatory medication), and epinephrine (a medication to constrict blood...” NCT04074265 ↗ “The addition of adrenaline (epinephrine) 1:80 000 to lignocaine 2 % is considered the gold-standard regimen because it prolongs pulpal anaesthesia, reduces peak plasma...” NCT07633106 ↗ “The "Control Arm" will receive an adductor canal catheter through which they will receive a 20 ml bolus of 0.25% bupivacaine with 1:400,000 epinephrine followed by an adductor...” NCT02991404 ↗ “A single-injection serratus plane block will be administered using ropivacaine 0.5% with epinephrine 1:200,000-400,000 (20 mL of local anesthetic for unilateral surgery; 16 mL...” NCT03860974 ↗ “Injection Cocktail includes: 10mg Morphine, 30mg Ketorolac, 3.5ug/ml (385ug total) of Ropivicaine, 2.5ug /ml (275ug total) Epinephrine with the remainder of the solution made...” NCT01667445 ↗ “A standard joint injection of 100ml (Clonidine 80 mcg, Epinephrine 0.5mg, Ketorolac 30mg, Ropivacaine 246.25mg, and Sodium Chloride 0.9% 48.45 ml) will be injected into the...” NCT02682498 ↗ “Patients in group 2 received an adductor canal block with 30 mL of ropivacaine 0.5% with 1:400,000 epinephrine, whereas patients in group 3 received the adductor canal block...” PMID 29315129 ↗ Feb 2018 |
| Known as | Adrenalin | “Standard thoracic epidural analgesia mixture (2 mg/ ml bupivacaine, 2 µg/ ml fentanyl and 2 µg/ ml adrenalin) with an infusion of 6-10 ml/hour until day 2 postoperatively.” NCT04025606 ↗15“epidural anesthesia: patients get an continuous infusion of a solution with bupivacain 1 mg/ml, fentanyl 1 ug/ml and adrenalin 1 ug/ml” NCT02030717 ↗ “Ropivacaine and Adrenalin, systemic Ketorolac and high dose Dexamethasone” NCT02374008 ↗ “30 ml of 0.25% BUPIVACAINE and ADRENALIN at 1: 200,000 concentration” NCT03395912 ↗ |
| Known as | Adrenalin (epinephrine) | “Adrenalin (epinephrine)” NCT05037812 ↗1“Adrenalin (epinephrine)” NCT05019638 ↗ |
| Known as | Adrenaline | “Participants in this arm received postoperative analgesia with periarticular infiltration consisting of 100 mg bupivacaine, 40 mg methylprednisolone, 0.5 mg adrenaline and...” NCT07849517 ↗106“20 ml of 0.5% bupivacaine added to them 50 μg adrenaline in a concentration of 1:400,000, were prepared by an assistant immediately before administration and injected in an...” NCT05381389 ↗ “Local anesthetic injection of articaine 4% + adrenaline 1/100.000 (Septanest, Septodont, Saint Maur des Fossés, France) with 30G - 9 mm needle (DENTAL HI TEC, ZI de...” NCT05531435 ↗ “We compared the effects of dopexamine and norepinephrine (noradrenaline) with those of epinephrine (adrenaline) on gastric mucosal blood flow (GMBF) in patients with septic shock.” PMID 16507156 ↗ Feb 2006 “Intrathecal 10 mg Heavy Marcaine, 200 mcg Morphine + High volume local anesthesia infiltration Bupivacaine 5mg/ml + adrenaline 5 mcg/ml 3mg/kg IBW diluted with 100cc Normal Saline” NCT03176758 ↗ “Guidelines recommend intramuscular injection of 500 μg adrenaline (epinephrine) for anaphylaxis in teenagers and adults; however, most autoinjectors deliver a maximum 300 μg dose.” PMID 36794963 ↗ Feb 2023 “Injection of 1,5 ml Xylocaine Dental Adrenaline (Lidocaine hydrochloride 20 mg/ml, adrenaline 12.5 µg/ml, Dentsply Pharmaceutical, Weybridge, Surrey, UK).” NCT02644811 ↗ “Local injection of Mepivacaine (10 mg/ml) and adrenaline (5 mcg/ml) approximately 10 ml in the incisional area at least 10 minutes before surgery start.” NCT06172400 ↗ “ultrasound guided Retrolaminar Block (RLB) with 20 ml (0.5% Bupivacaine) plus 5 mic/ml Adrenaline (1:200,000) at the level of T4 of the surgical side” NCT04531215 ↗ “Topical anesthesia gel will be applied followed by dental injection with 1.8 ml Xylocaine 20mg/ml (DENSPLY Pharmaceutical); adrenaline: 1 : 100.000” NCT04919421 ↗ “Epinephrine (adrenaline) vasoconstricts arteries, delaying the resorption of lidocaine, and thus almost doubles the duration of anesthesia.” NCT03913845 ↗ |
| Known as | DESF | “This study is designed to evaluate the pharmacokinetics (PK) of epinephrine administered as a single dose of DESF.” NCT07703982 ↗ |
| Known as | E004 | “This study examines the pharmacokinetic profile of Armstrong's proposed Epinephrine Inhalation Aerosol USP, an HFA-MDI (E004), using a stable isotope deuterium-labeled...” NCT01188577 ↗2“E004 (epinephrine inhalation aerosol), 90 mcg/actuation” NCT01025648 ↗ “Experimental arm utilizing Epinephrine HFA-MDI (E004)” NCT01737905 ↗ |
| Known as | Emerade | “500 μg epinephrine auto-injector (Emerade, Bausch and Lomb, 23 mm needle length)” NCT03282929 ↗ |
| Known as | epi | “2.5 mL of 2% Lidocaine with 1:100,000 epi will be infiltrated at anterior teeth” NCT03368391 ↗1“Lidocaine w/ Epi” NCT01243112 ↗ |
| Known as | Epinephrin | “Drug: Epinephrin 0.03” NCT05051150 ↗ |
| Known as | epinephrine (adrenaline) hydrochloride | “Articaine hydrochloride/epinephrine (adrenaline) hydrochloride” NCT03354312 ↗ |
| Known as | Epinephrine 1mg/ml - Pt. Pharos Tbk | “Epinephrine 1mg/ml - Pt. Pharos Tbk” NCT06789549 ↗ |
| Known as | Epinephrine Bitartrate | “Participants in this group received local anesthesia consisting of 2% mepivacaine hydrochloride with 1:55,000 (0.018 mg/mL) epinephrine bitartrate prior to simple mandibular...” NCT07013071 ↗ |
| Known as | Epinephrine CFC-MDI | “A previously marketed Epinephrine CFC-MDI, labeled "For Investigational Use Only" will be used as a Reference Control (Arm C).” NCT01737892 ↗ |
| Known as | epinephrine Hcl | “and 0.5 mg of epinephrine Hcl (2 vials of Epinephrine® 0.25mg/1ml Misr Co. for Pharmaceutical Industries)” NCT05806307 ↗ |
| Known as | Epinephrine Inhalation Aerosol - CFC | “Epinephrine Inhalation Aerosol - CFC, Single dose 220 mcg, 1 inhalation” NCT01737892 ↗ |
| Known as | Epinephrine Inhalation Solution | “Drug: Epinephrine Inhalation Solution” NCT05006235 ↗ |
| Known as | Epinephrine Injection | “Drug: Epinephrine Injection” NCT05166343 ↗ |
| Known as | L-Epinephrine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01276821 ↗ |
| Known as | Levogira | “dexamethasone and epinephrine (Levogira) (ED)” NCT02585531 ↗ |
| Action | Activate | “epinephrine, is an alpha- and beta- adrenergic agonist” NCT02371759 ↗ |
| Modality | Other / unclassified | “In septic shock, when volume resuscitation fails to restore mean arterial pressure, catecholamines such as dopamine, dobutamine, epinephrine, or norepinephrine are used, either...” NCT00134212 ↗ |
| Route | Other | “intratumoral injection of a cisplatin/epinephrine gel (CDDP-e TI)” NCT00002659 ↗ |